Every 10-Q that BIOADAPTIVES INC (BDPT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BDPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDPT filings page.
BIOADAPTIVES, INC. (BDPT) reported a small net profit for the three and six months ended June 30, 2026, driven primarily by non‑cash derivative valuation gains rather than core operations. For the quarter, revenue was $4,988 with a gross profit of $4,240, while operating expenses of $201,416 produced an operating loss of $197,176.
Other income of $347,266, mainly a $446,730 gain from the change in fair value of derivative liabilities, led to quarterly net income of $150,090 (basic EPS $0.01). For the first half, revenue totaled $10,502, the operating loss was $395,394, and net income was $39,004 versus a $355,050 loss a year earlier.
The balance sheet remains highly stressed: total assets were only $78,767 against total liabilities of $1,844,874, including $1,050,397 of derivative liabilities and $490,629 of current convertible notes. Stockholders’ deficit was $1,766,107, with an accumulated deficit of $10,682,200. Management discloses substantial doubt about the company’s ability to continue as a going concern, cites material weaknesses in internal control, and notes defaults on legacy 12% debentures while seeking additional financing and relying on equity issuances.
BioAdaptives Inc. reported a net loss of $111,086 for the quarter ended March 31, 2026, an improvement from a loss of $197,136 a year earlier, as operating expenses declined. The company recorded its first reported revenues of $5,514, generating a small gross profit of $4,113, but its business remains at an early stage.
Liquidity is very tight. Cash was only $73,606 and total current assets $123,449, versus current liabilities of $2,272,091, resulting in a working capital deficit and a stockholders’ deficit of $2,136,142. This includes sizeable derivative liabilities of $1,563,920 and convertible notes of $424,211, all current.
Management states that recurring losses and the need for additional capital raise substantial doubt about the company’s ability to continue as a going concern. To conserve cash, BioAdaptives issued $105,000 of Series D preferred stock as compensation and continues to rely on related-party financing. Internal controls over financial reporting are deemed ineffective due to material weaknesses. The company is rolling out new nutraceutical and pet-health products, including PawPa Regen, MyndMed, Xcellara and, after quarter-end, the MyndSystem line, but these launches have not yet offset ongoing operating and financing pressures.
BioAdaptives, Inc. (BDPT) reported Q3 2025 results, showing a wider net loss and continued liquidity pressure. Net loss was $379,502 for the quarter, compared with $37,649 a year ago, as operating expenses and derivative fair value changes weighed on results. Revenue reached $4,632 in Q3 as limited PawPa Regen sales began.
For the nine months, net loss totaled $734,552 on revenue of $7,851. Cash was $59,273 at September 30, 2025, with current assets of $108,860 versus current liabilities of $1,589,570, resulting in a working capital deficiency of $1,480,710. The company reported a stockholders’ deficit of $1,465,210, including derivative liabilities of $967,406 and convertible notes of $359,300.
Management disclosed substantial doubt about the company’s ability to continue as a going concern and noted material weaknesses in internal controls. Financing activities included $300,000 of cash proceeds from Series D preferred stock and debt-to-equity conversions. Common shares outstanding were 12,008,659 as of October 17, 2025.